{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:56:12Z","timestamp":1790805372979,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009980","name":"Medizinische Universit\u00e4t Innsbruck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.08.020","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:29:44Z","timestamp":1788823784000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term Elexacaftor\/Tezacaftor\/Ivacaftor Therapy Improves Glucose Tolerance and Lowers Insulin Concentrations in Cystic Fibrosis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0030-5356","authenticated-orcid":false,"given":"Dorothea","family":"Appelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Ruetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Niedermayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Ellemunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2026.08.020_bib1","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.08.020_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"159","key":"10.1016\/j.eprac.2026.08.020_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0293-2020","article-title":"Cystic fibrosis-related diabetes and lung disease: an update","volume":"30","author":"Prentice","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.eprac.2026.08.020_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.diabres.2015.10.007","article-title":"Glucose intolerance in cystic fibrosis as a determinant of pulmonary function and clinical status","volume":"110","author":"Lavie","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 27","key":"10.1016\/j.eprac.2026.08.020_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD clinical practice consensus guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents","volume":"19","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"10.1016\/j.eprac.2026.08.020_bib6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.08.020_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/clinem\/dgad443","article-title":"Preservation of \u03b2-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy","volume":"109","author":"Flatt","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2026.08.020_bib8","article-title":"One-year effect of elexacaftor\/tezacaftor\/ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: a retrospective observational study","volume":"14","author":"Bassi","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.eprac.2026.08.020_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.03.007","article-title":"Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor","author":"Wood","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2026.08.020_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"23","author":"Nielsen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.08.020_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111839","article-title":"Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice","volume":"216","author":"Aguilera Garc\u00eda","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.08.020_bib12","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.08.020_bib13","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1164\/rccm.202411-2312OC","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance and abnormal glucose metabolism: a phase 3b, open-label clinical trial","volume":"211","author":"Durieu","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.08.020_bib14","article-title":"Glycemia and insulin secretion in cystic fibrosis two years after elexacaftor\/tezacaftor\/ivacaftor: promise-endo","author":"Chan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.08.020_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic Fibrosis-An observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"4","key":"10.1016\/j.eprac.2026.08.020_bib16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.08.020_bib17","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf099","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance in adolescents with cystic fibrosis","author":"Galderisi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.08.020_bib18","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2026.08.020_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2026.02.019","article-title":"The changing landscape of pediatric endocrinology in cystic fibrosis: insights from the Post-CFTR modulator era","author":"Scully","year":"2026","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2026.08.020_bib20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-3476(89)80438-X","article-title":"Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity","volume":"114","author":"Caprio","year":"1989","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.eprac.2026.08.020_bib21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.08.020_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jcf.2019.07.006","article-title":"Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia","volume":"19","author":"Kilberg","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.08.020_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1623654","article-title":"Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review","volume":"16","author":"Giordano","year":"2025","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2026.08.020_bib24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s13300-017-0265-4","article-title":"A practical review of C-Peptide testing in diabetes","volume":"8","author":"Leighton","year":"2017","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.eprac.2026.08.020_bib25","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0690","article-title":"Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis","volume":"15","author":"Edlund","year":"2026","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.eprac.2026.08.020_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030469","article-title":"Distribution of OGTT-related variables in patients with cystic fibrosis from puberty to adulthood: an Italian multicenter study","volume":"13","author":"Foppiani","year":"2023","journal-title":"J Pers Med"},{"issue":"3 Pt 1","key":"10.1016\/j.eprac.2026.08.020_bib27","first-page":"E349","article-title":"Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans","volume":"254","author":"Tillil","year":"1988","journal-title":"Am J Physiol"},{"issue":"12","key":"10.1016\/j.eprac.2026.08.020_bib28","article-title":"An update in cystic fibrosis-related diabetes in children and adolescents","volume":"10","author":"Anton-P\u0103duraru","year":"2023","journal-title":"Children (Basel)"},{"issue":"2","key":"10.1016\/j.eprac.2026.08.020_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:01:52Z","timestamp":1790802112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26011225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S1530891X26011225"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.08.020","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Elexacaftor\/Tezacaftor\/Ivacaftor Therapy Improves Glucose Tolerance and Lowers Insulin Concentrations in Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}